Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | ADH4 | P08319 | 1/20 | 0.36 |
| ▸ | ADH7 | P40394 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TOP1 | P11387 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9304796 | 0.98 | LMNA (0.46) | LMNATSHRDNM1FAAHTRPV1 | |
| SCHEMBL7176175 | 0.91 | TSHR (0.41) | LMNATSHRDNM1FAAHTRPV1 | |
| SCHEMBL9784135 | 0.86 | LMNA (0.48) | LMNATSHRDNM1FAAHTRPV1 | |
| SCHEMBL2484070 | 0.85 | ACE2 (0.44) | LMNATSHRDNM1FAAHTRPV1 | |
| SCHEMBL4663853 | 0.85 | ACE2 (0.44) | LMNATSHRDNM1FAAHTRPV1 | |
| SCHEMBL2483185 | 0.85 | ACE2 (0.44) | LMNATSHRDNM1FAAHTRPV1 | |
| SCHEMBL28049407 | 0.84 | FAAH (0.50) | LMNAFAAHTRPV1TOP1 | |
| SCHEMBL28049384 | 0.84 | FAAH (0.50) | LMNAFAAHTRPV1TOP1 | |
| SCHEMBL28049414 | 0.84 | FAAH (0.50) | LMNAFAAHTRPV1TOP1 | |
| SCHEMBL7105674 | 0.84 | LMNA (0.44) | LMNATSHRDNM1ADH1BADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009155657-A1 | CONDUCTING AND SEMICONDUCTING ORGANIC MATERIALS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2009-12-30 | — | — | WO | disclosed |
| US-7122673-B2 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2006-10-17 | — | — | US | disclosed |
| US-20030208076-A1 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | AUSTRALIAN NATIONAL UNIVERSITY, THE (AU) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208076-A1 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | HCCS, CYCS, CCNO | LMNA 1374/4885TSHR 3474/4885DNM1 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.